Incomplete radiation therapy common among medicare recipients with head and neck cancer

September 21, 2009,

Medicare recipients with head and neck cancer commonly do not complete radiation therapy without interruptions or at all, according to a report in the September issue of Archives of Otolaryngology-Head & Neck Surgery. Patients who have surgery before radiation treatment appear more likely to complete therapy, whereas those who have other illnesses or who have chemotherapy first may be more likely to experience interruptions or discontinuation in radiation treatment.

Head and neck cancers are a complex group of tumors that involve the sinuses, lips, mouth, pharynx and larynx, according to background information in the article. "Radiotherapy [] alone or as an adjuvant to surgery and/or chemotherapy has been shown to be curative in patients with local or regional head and neck cancers," the authors write. "Clinical evidence suggests that the radiation dose and duration of treatment is correlated with tumor control and survival. Breaks in radiotherapy have been associated with inferior tumor control in the larynx, pharynx and oral cavity."

Megan Dann Fesinmeyer, Ph.D., M.P.H., of Fred Hutchinson Cancer Research Center, Seattle, and colleagues used cancer registries linked to Medicare data to identify 5,086 patients diagnosed with head and neck cancer between 1997 and 2003. They then calculated the timing and duration of radiotherapy using Medicare claims data, and performed analyses to estimate the association between tumor and clinical characteristics and any interruptions or discontinuation of therapy.

A substantial percentage of patients (39.8 percent) had interruptions in radiation therapy or failed to complete the course of therapy. Patients who had surgery at any tumor site were more likely to complete radiotherapy with no interruptions (70.4 percent, vs. 52 percent of those who did not have surgery). However, patients with co-occurring illnesses, those who underwent chemotherapy and those whose disease had spread to surrounding lymph nodes were less likely to do so.

"Surgical patients may be more likely to complete radiotherapy for several reasons. First, characteristics that make patients good candidates for surgery may also make them more likely to complete radiotherapy. Because comorbidities are known to decrease survival in patients with head and , healthier patients may be chosen by surgeons to complete more rigorous treatments (e.g., surgery in addition to radiotherapy)," the authors write. "In addition, patients who are willing to undergo major surgery to treat their disease may also be more motivated to complete a full course of uninterrupted radiation therapy, despite any toxic effects of treatment that may occur."

Further research is needed to understand the factors associated with interruptions or failure to complete radiation therapy among patients who do not have surgery, the authors conclude. "Because chemotherapy appears to reduce the likelihood of completing radiotherapy, future research is needed to identify specific agents, doses and schedules that specifically reduce the likelihood of completing treatment in community settings," they write.

More information: Arch Otolaryngol Head Neck Surg. 2009;135[9]:860-867.

Source: JAMA and Archives Journals (news : web)

Related Stories

Recommended for you

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.